PLEKHA5

Across TCGA pan-cancer cohorts, PLEKHA5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA5 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLEKHA5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHA5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where PLEKHA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.971	0.693	<.001	33	view →
CCRCC	DFS	Median	All	0.625	0.851	.014	16	view →
LSCC	DFS	Median	III,IV	1.000	0.599	.001	11	view →
GBM	OS	Quartile	All	0.813	1.000	.001	8	view →
LUAD	DFS	Tertile	III,IV	0.522	0.948	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA5–PDAC (OS)

Open the PDAC breakdown →